—Clinical Data from Phase 2 SPRING Trial Shows that CM-101 Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis— TEL AVIV, Israel, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from its Phase 2 SPRING trial in patients with primary sclerosing cholangitis (PSC) was presented at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024. In the oral, late-breaking presentation, "CM-101 i

──FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter 2024 to Discuss the Design of a CM-101 Accelerated Approval Phase 3 Trial in Primary Sclerosing Cholangitis (PSC)── ──Cash Runway Extended to Early 2026; Continuing Discussions with Potential Strategic Partners; Preparations Underway to Advance CM-101 to Phase 3 in Late 2025── TEL AVIV, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2024, and provided a corporate update

TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd.                                                     

TEL AVIV, Israel, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its late breaking abstract discussing the results of the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) has been selected for an oral presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024. The conference will take place in San Diego, California, November 15 – 19, 2024. Professor Christopher Bowlus, MD, FAASLD, the Lena Valente Professor and Chief of the Division of Gastroe

TEL AVIV, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that senior management will participate in two upcoming investor conferences. Chemomab management will meet with investors at the Third Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York City on October 9, 2024, and Chemomab co-founder and Chief Executive Officer Dr. Adi Mor will participate in a fireside chat with senior biotechnology analyst Michael Okunewitch at the Maxim Healthcare Virtual Summit on Oct

TEL AVIV, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver corporate presentations at the H.C. Wainwright 26th Annual Global Investment Conference and at the HBM Biopharma Summit 2024 in Zurich, Switzerland. Dr. Mor's prerecorded H.C. Wainwright presentation will be webcast and is available starting on September 9, 2024 at 7:00 am ET. The link to access the webcast is included below and is also available at the Events section of the Chemomab website.

──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)── ──Establishes Clinical Proof-of-Concept for Disease-Modifying Potential of CM-101 and Provides Foundation for Advancing to PSC Phase 3 Pivotal Trial── ──Completed PIPE Financing Including Major New and Existing Investors that Extends Cash Runway Through Beginning of 2026── ──On Track to Achieve Key Clinical Milestones in First Quarter of 2025; Continuing Discussions with Potential Partners── TEL AVIV, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Che

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company

— HBM Healthcare Investments, OrbiMed and Sphera Biotech Master Fund LP Participated in the Financing that Extends Cash Runway Potentially to the Beginning of 2026— —Chemomab is Well-Positioned to Achieve Key Clinical Milestones in Q1 2025 While Continuing to Advance Its Discussions with Potential Partners Based on Positive Phase 2 Results— TEL AVIV, Israel, July 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it had closed a private placement that resulted in gross proceeds of approxi

TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Chemomab had previously announced on November 6, 2023, that it was notified by Nasdaq that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing

Maxim Group initiated coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $4.00

Oppenheimer upgraded Chemomab Therapeutics from Perform to Outperform and set a new price target of $6.00

ROTH MKM resumed coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $7.00

Oppenheimer reiterated coverage of Chemomab Therapeutics with a rating of Outperform and set a new price target of $20.00 from $30.00 previously

Aegis Capital initiated coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $30.00

Cantor Fitzgerald initiated coverage of Chemomab Therapeutics with a rating of Overweight and set a new price target of $45.00

Oppenheimer initiated coverage of Chemomab Therapeutics with a rating of Outperform and set a new price target of $42.00

TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd.                                                     

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company

First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC), Establishing Clinical Proof-of-Concept for the Disease-Modifying Potential of CM-101 Treatment with CM-101 Led to Statistically Significant Improvements in Liver Stiffness, a Well-Validated Biomarker of Disease Progression in PSC Treatment with CM-101 Led to Statistically Significant Improvements in Pruritis and Improvements in Total Bilirubin and Liver Function Tests Positive Phase 2 Data Paves Way f

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd.Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflam

TEL AVIV, Israel, Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the press release is issued are invited to contact the company at IR@chemo

─Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and Inflammatory Biomarkers─ ─Received FDA Clearance for CM-101 Systemic Sclerosis IND—Phase 2 Trial Expected to Open Mid-year─ ─Advancing Phase 2 PSC Trial and Enrolling Patients in Higher Dose Cohort ─ ─Extending Estimated Cash Runway Through First Half of 2024─  ─Company to Host Conference Call for Investors Today, May 11 at 8:00 am ET ─ TEL AVIV, Israel, May 11, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeu

This Webcast and Call Replaces and Supplements the Chemomab Corporate Update Originally Scheduled for April 17, 2023 TEL AVIV, Israel, April 12, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its first quarter 2023 financial results and provide a corporate update on Thursday, May 11, 2023, at 8:00 am Eastern Time.   This webcast and call replaces and s

TEL AVIV, Israel, March 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will provide a Corporate Update on Monday, April 17, 2023, at 8:00 am Eastern Time. This event replaces the webcast and call originally scheduled for March 31, 2023. During the event, Chemomab's management team will review recent corporate developments and conduct a live question-and-answer

TEL AVIV, Israel, March 17, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its fourth quarter and full-year 2022 financial results and provide a business update on Friday, March 31, 2023, at 8:00 am Eastern Time.  During the event, Chemomab's management team will review fourth quarter and full-year 2022 performance, discuss recent and upcoming developm

 ─Chemomab to Host Conference Call for Investors Today, November 11 at 8:00 am ET─ TEL AVIV, Israel, Nov. 11, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2022 and provided a corporate update. "We continued to make good progress in advancing our clinical programs for CM-101 during the third quarter," said

TEL AVIV, Israel, Nov. 30, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy. Dr. Jones brings Chemomab more than 15 years of leadership experience in biopharmaceutical research, clinical development, corporate strategy and entrepreneurship, organizational development and team-building, technology transfer and licensing and acquisitions. He will be responsible for spearheading the corpor

TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Matthew Frankel, MD, MBA as Chief Medical Officer (CMO) and Vice President of Drug Development. "We believe Dr. Frankel's wealth of experience across all aspects of clinical development and medical affairs, along with his outstanding performance in helping to bring biologic and

─Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President  of Clinical Development─ TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development. "Ch

—Ms. Quigley's Broad Biotechnology Industry Experience Encompasses Leadership Positions in Executive Management, Operations and Legal Affairs— TEL AVIV, Israel, June 21, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that Jill M. Quigley, JD, has been appointed to the Chemomab board of directors. Ms. Quigley brings more than 20 years of biotechnology industry leadership experience encompassing executive management, corporate operations, legal affairs, financings, and board membership

TEL AVIV, Israel, Dec. 16, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab) a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that, as planned and announced earlier this year, CEO Dale R. Pfost, PhD will assume the additional role of Chairman, subject to the approval of Chemomab's shareholders, as is required under Israeli law. A shareholder vote is expected to be held in or around February 2022. Stephen Squinto, PhD, will be leaving his current positions as Chairman of the Chemomab board and as a director of the company, effective Dec

TEL AVIV, Israel, Sept. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for inflammatory and fibrotic diseases with high unmet need, today announced it has appointed Dale R. Pfost, PhD, as Chief Executive Officer (CEO). Dr. Adi Mor, Company co-founder and current CEO, will continue in her role as Chief Scientific Officer (CSO) and remain as a member of the Board of Directors. The addition of Dr. Pfost, who brings more than 30 years of diverse experience as a life science senior executive, entrepreneur and venture investor, reflects a planned strategic expansion of the Chemom

TEL-AVIV, Israel, March 29, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the appointment of Dr. Alan Moses, Dr. Claude Nicaise, Mr. Joel Maryles, and Mr. Neil Cohen to Chemomab's Board of Directors. Dr. Stephen Squinto will remain Chairman of Chemomab's Board. Dr. Adi Mor and Dr. Nissim Darvish will also continue in their prior role as Directors, where Dr. Darvish will serve as Chair of the Compensation Committee. Chemomab also closed its previously announced private investment in public equity (PIPE) and

6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

424B5 - Chemomab Therapeutics Ltd. (0001534248) (Filer)

6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

424B3 - Chemomab Therapeutics Ltd. (0001534248) (Filer)

EFFECT - Chemomab Therapeutics Ltd. (0001534248) (Filer)

F-3 - Chemomab Therapeutics Ltd. (0001534248) (Filer)

6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

D - Chemomab Therapeutics Ltd. (0001534248) (Filer)

6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

Pursuant to the terms of the securities purchase agreement, the Company is selling to certain investors (i) 4,188,867 American Depositary Shares ("ADSs"), each representing twenty (20) ordinary shares of the Company, no par value per share, at a purchase price of $1.235 per share which reflects the average share price on the Nasdaq for the last 4 trading days (ii), in lieu of ADSs, pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 3,908,300 ADSs at a price per Pre-Funded Warrant of $1.235. The Pre-Funded Warrants have an exercise price of $0.0001 per ADS, are immediately exercisable and remain exercisable until exercised in full. The PIPE is expected to close on or about 

https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12018074

Maxim Group analyst Michael Okunewitch initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and announces Price Target of $4.

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share. This is a 65 percent increase over losses of $(0.80) per share from the same period last year.

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 35.61% to $1.98. The company's market cap stands at $6.3 million. Outset Medical (NASDAQ:OM) stock rose 26.15% to $3.96. The company's market cap stands at $204.8 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 25.66% to $1.42. The market value of their outstanding shares is at $16.7 million. Chemomab Therapeutics (NASDAQ:CMMB) stock rose 22.16% to $0.9. The market value of their outstanding shares is at $12.8 million. Titan Pharma (NASDAQ:TTNP) shares moved u

SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)

SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)

SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

SC 13G/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

SC 13D - Chemomab Therapeutics Ltd. (0001534248) (Subject)

SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)